Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 168

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

Rodriguez, Pedro C., Popa, Xitllaly, Martínez, Odeth, Mendoza, Silvia, Santiesteban, Eduardo, Crespo, Tatiana, Amador, Rosa M., Fleytas, Ricardo, Acosta, Soraida C., Otero, Yanine, Romero, Gala N., de la Torre, Ana, Cala, Mireysi, Arzuaga, Lina, Vello, Loisel, Reyes, Delmairis, Futiel, Niurka, Sabates, Teresa, Catala, Mauricio, Flores, Yoanna I., Garcia, Beatriz, Viada, Carmen, Lorenzo-Luaces, Patricia, Marrero, Maria A., Alonso, Liuba, Parra, Jenelin, Aguilera, Nadia, Pomares, Yaisel, Sierra, Patricia, Rodríguez, Gryssell, Mazorra, Zaima, Lage, Agustin, Crombet, Tania, Neninger, Elia · 2016 · Clinical Cancer Research

Abstract

Purpose: EGFR is a well-validated target for patients with non–small cell lung cancer (NSCLC). CIMAvax-EGF is a therapeutic cancer vaccine composed of human recombinant EGF conjugated to a carrier protein and Montanide ISA51 as adjuvant. The vaccine is intended to induce antibodies against self EGFs that block EGF–EGFR interaction. Experimental Design: To evaluate overall survival, safety, immunogenicity, and EGF concentration in serum after CIMAvax-EGF, a randomized phase III trial was done in patients with advanced NSCLC. Four to 6 weeks after first-line chemotherapy, 405 patients with stage IIIB/IV NSCLC were randomly assigned to a vaccine group, which received CIMAvax-EGF or a control group, treated with best supportive care. Results: Long-term vaccination was very safe. Most frequent adverse reactions were grade 1 or 2 injection-site pain, fever, vomiting, and headache. Vaccination induced anti-EGF antibodies and decreased serum EGF concentration. In the safety population, median survival time (MST) was 10.83 months in the vaccine arm versus 8.86 months in the control arm. These differences were not significant according the standard log rank (HR, 0.82; P = 0.100), but according a weighted log rank (P = 0.04) that was applied once the nonproportionality of the HR was verified. Survival benefit was significant (HR, 0.77; P = 0.036) in the per-protocol setting (patients receiving at least four vaccine doses): MST was 12.43 months for the vaccine arm versus 9.43 months for the control arm. MST was higher (14.66 months) for vaccinated patients with high EGF concentration at baseline. Conclusions: Switch maintenance with CIMAvax-EGF was well tolerated and significantly increased MST of patients that completed induction vaccination. Baseline EGF concentration predicted survival benefit. Clin Cancer Res; 22(15); 3782–90. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0855

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 168

Metadata

Authors
Rodriguez, P. C., Popa, X., Martínez, O., Mendoza, S., Santiesteban, E., Crespo, T., Amador, R. M., Fleytas, R., Acosta, S. C., Otero, Y., Romero, G. N., de la Torre, A., Cala, M., Arzuaga, L., Vello, L., Reyes, D., Futiel, N., Sabates, T., Catala, M., Flores, Y. I., Garcia, B., Viada, C., Lorenzo-Luaces, P., Marrero, M. A., Alonso, L., Parra, J., Aguilera, N., Pomares, Y., Sierra, P., Rodríguez, G., Mazorra, Z., Lage, A., Crombet, T., & Neninger, E.
Venue
Clinical Cancer Research
Published
2016-07-31
Volume
22
Issue
15
Pages
3782-3790
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2288565689
Cited by
168
References
3
FWCI
16.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0855
The paper
Rodriguez, P. C., Popa, X., Martínez, O., Mendoza, S., Santiesteban, E., Crespo, T., Amador, R. M., Fleytas, R., Acosta, S. C., Otero, Y., Romero, G. N., de la Torre, A., Cala, M., Arzuaga, L., Vello, L., Reyes, D., Futiel, N., Sabates, T., Catala, M., . . . Neninger, E. (2016). A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0855

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.